The Economic Burden of Biological Drugs in Rheumatoid Arthritis
Treatment

J 2024

The Economic Burden of Biological Drugs in Rheumatoid Arthritis Treatment

GREGA, Dominik and Jozef KOLÁŘ

Basic information

Original name

The Economic Burden of Biological Drugs in Rheumatoid Arthritis Treatment

Authors

GREGA, Dominik (703 Slovakia, guarantor, belonging to the institution) and Jozef KOLÁŘ (203 Czech Republic, belonging to the institution)

Edition

Value in Health Regional Issues, AMSTERDAM, Elsevier, 2024, 2212-1099

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30104 Pharmacology and pharmacy

Country of publisher

Netherlands

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 2.000 in 2022

Organization unit

Faculty of Pharmacy

DOI

http://dx.doi.org/10.1016/j.vhri.2023.10.001

UT WoS

001117176500001

Keywords in English

direct costs; elasticity factor; friction period; indirect costs; loss of productivity.

Abstract

V originále

Objectives: This article aimed to count and compare treatment's direct (only biological drugs) and indirect (loss of productivity) costs in patients with rheumatoid arthritis from 2019 to 2021.Methods: The friction cost approach was used to establish indirect costs. Elasticity factor values and friction period for the Slovak Republic from 2019 to 2021 were determined. Direct drug costs were calculated based on average prices from 2019 to 2021 and the number of dispensed medication packages.Results: The average productivity loss reached euro2984.54 in 2019, euro3338.46 in 2020, and euro3154.01 in 2021. Total indirect costs include productivity loss and sick pay, and from 2019 to 2021 came the values of euro8.4 million, euro10.1 million, and euro8.1 million, respectively. Conclusions: Indirect costs were almost 2.5 to 3 times lower than the biological and targeted treatment costs.

Citovat

GREGA, Dominik and Jozef KOLÁŘ. The Economic Burden of Biological Drugs in Rheumatoid Arthritis Treatment. Value in Health Regional Issues. AMSTERDAM: Elsevier, 2024, vol. 40, March, p. 13-18. ISSN 2212-1099. Available from: https://dx.doi.org/10.1016/j.vhri.2023.10.001.

@article{2361031,
   author = {Grega, Dominik and Kolář, Jozef},
   article_location = {AMSTERDAM},
   article_number = {March},
   doi = {http://dx.doi.org/10.1016/j.vhri.2023.10.001},
   keywords = {direct costs; elasticity factor; friction period; indirect costs; loss of productivity.},
   language = {eng},
   issn = {2212-1099},
   journal = {Value in Health Regional Issues},
   title = {The Economic Burden of Biological Drugs in Rheumatoid Arthritis Treatment},
   url = {https://www.valuehealthregionalissues.com/article/S2212-1099(23)00109-7/fulltext},
   volume = {40},
   year = {2024}
}

TY  - JOUR
ID  - 2361031
AU  - Grega, Dominik - Kolář, Jozef
PY  - 2024
TI  - The Economic Burden of Biological Drugs in Rheumatoid Arthritis Treatment
JF  - Value in Health Regional Issues
VL  - 40
IS  - March
SP  - 13-18
EP  - 13-18
PB  - Elsevier
SN  - 22121099
KW  - direct costs
KW  - elasticity factor
KW  - friction period
KW  - indirect costs
KW  - loss of productivity.
UR  - https://www.valuehealthregionalissues.com/article/S2212-1099(23)00109-7/fulltext
N2  - Objectives: This article aimed to count and compare treatment's direct (only biological drugs) and indirect (loss of productivity) costs in patients with rheumatoid arthritis from 2019 to 2021.Methods: The friction cost approach was used to establish indirect costs. Elasticity factor values and friction period for the Slovak Republic from 2019 to 2021 were determined. Direct drug costs were calculated based on average prices from 2019 to 2021 and the number of dispensed medication packages.Results: The average productivity loss reached euro2984.54 in 2019, euro3338.46 in 2020, and euro3154.01 in 2021. Total indirect costs include productivity loss and sick pay, and from 2019 to 2021 came the values of euro8.4 million, euro10.1 million, and euro8.1 million, respectively. Conclusions: Indirect costs were almost 2.5 to 3 times lower than the biological and targeted treatment costs.
ER  -

GREGA, Dominik and Jozef KOLÁŘ. The Economic Burden of Biological Drugs in Rheumatoid Arthritis Treatment. \textit{Value in Health Regional Issues}. AMSTERDAM: Elsevier, 2024, vol.~40, March, p.~13-18. ISSN~2212-1099. Available from: https://dx.doi.org/10.1016/j.vhri.2023.10.001.

Detailed Information on Publication Record